Injuries Caused by Accutane®
Call Today: 877-612-9867
Contact us for free information or to start a free case review.
AccutaneŽ is an acne medication that was approved as a last resort for the most severe instances of acne. First available in 1982, there have been links to AccutaneŽ side effects, especially in pregnant women. Females who are on AccutaneŽ during their pregnancy risk serious birth defects, including severe brain and heart defects, mental retardation, as well as other risks. The FDA has been widely criticized for its failure to implement stricter restrictions on the drug even in light of the continued reports of AccutaneŽ pregnancy.
Public Citizen consumer group petitioned the FDA to give patients warning information with the drug in 1983. This was just one year after AccutaneŽ was released. The length of time AccutaneŽ has been on the market, along with the continuation of AccutaneŽ pregnancy reports being made, was the reason the consumer group later petitioned for an AccutaneŽ ban in 1988. Numbers show that about 25 percent of AccutaneŽ pregnancy births will result in serious birth defects and 50 percent of the AccutaneŽ pregnancy births will result in mental disability.
Due to the high rate of birth defects, the majority of women that have an AccutaneŽ pregnancy choose to have an abortion. It is estimated that 26 times more women than necessary are prescribed AccutaneŽ. In 2001, the FDA began to urge pregnancy testing and contraceptive education in hopes of reducing the number of AccutaneŽ pregnancy reports but has also admitted it was a voluntary system that has had no effect.
Since hitting the market, the FDA has received well over 2,000 reports of AccutaneŽ pregnancy. The actual AccutaneŽ pregnancy number is believed to be much higher due to underreporting. Also, this is due to the fact that doctors are not required to report AccutaneŽ linked pregnancies to the FDA. Warnings continued to fail to have any impact on the AccutaneŽ pregnancy numbers so in 2001, the FDA's own advisory committee recommended a registry.
In April 2002, the FDA and AccutaneŽ manufacturer, Hoffmann-La Roche, launched a program to reduce the AccutaneŽ pregnancy numbers. Despite the program, within the first year, the numbers showed that there was no improvement. The inability to adequately address the problem of AccutaneŽ pregnancies over the last twenty years that the dangers of AccutaneŽ have been known, will lead Public Citizen to petition the FDA again, according to a February 2004 presentation.
Now, the FDA is debating guidelines for tighter restrictions that could finally reduce the AccutaneŽ pregnancy and birth defects numbers. Public Citizen believes photographic evidence of severe cystic acne and proof that the patient has not responded to other acne medications should be required. In addition, women should have a written statement detailing their contraceptive practices and be able to show negative pregnancy tests.
If you are someone you love has experienced an injury from using AccutaneŽ, please contact our experienced AccutaneŽ lawyers now!
The side effects that are associated with AccutaneŽ are relatively well known, but less attention is typically paid to generic versions of the drug that use the ...
A recent study has found that the adverse side effects associated with isotretinoin, the active ingredient in AccutaneŽ, may be reduced if the patient takes smal...
A recent study published the American Journal of Gastroenterology, isotretinoin, whose brand name is Accutane, can cause a number of inflammatory bowel diseases.
...
Copyright Š 2001 - 2012 Online Lawyer Source | Legal Marketing Site Designed by eJustice
ATTORNEY ADVERTISEMENT—Thank you for your visit. The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. Furthermore, the information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. The material published on this site is general and may not apply to your specific circumstances. Every case comes with its own set of unique circumstances; past success discussed on this site does not guarantee future performance. Information found on this website should not be used as incentive to act without seeking counsel from a professional. For more information, please read our disclaimer.